A Canadian Study of the Cost-Effectiveness of Apixaban Compared With Enoxaparin for Post-Surgical Venous Thromboembolism Prevention

Revankar, Nikhil; Patterson, John W.; Kadambi, Ananth; Raymond, Vincent; El-Hadi, Wissam

doi:10.3810/pgm.2013.07.2686

Cited by 22 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A cost analysis using the ADVANCE studies indicated improved cost-effectiveness with the use of apixaban compared with enoxaparin. 44 In line with these findings, a comparison of all Factor Xa inhibitors with the 2 LMWH agents (enoxaparin and dalteparin) found the Factor Xa inhibitors to be the economically superior option. 45 Fondaparinux.…”

Section: Novel Factor Xa Inhibitorsmentioning

confidence: 75%

Venous Thromboembolism Prophylaxis After Total Joint Arthroplasty

Flierl¹,

Messina²,

Mitchell³

et al. 2015

Orthopedics

View full text Add to dashboard Cite

Venous thromboembolism (VTE) prophylaxis after total joint arthroplasty is considered best practice. However, over the past 5 years, there has been considerable debate about the ideal prophylactic regimen or modality. The American Academy of Orthopaedic Surgeons and the American College of Chest Physicians published their most recent clinical practice guidelines about VTE prophylaxis in 2011 and 2012, respectively. In addition, the Surgical Care Improvement Project published their latest recommendations in 2014. In this review, commonly used VTE prophylaxis options and the latest clinical guidelines will be discussed.

show abstract

Section: Novel Factor Xa Inhibitorsmentioning

confidence: 75%

Venous Thromboembolism Prophylaxis After Total Joint Arthroplasty

Flierl¹,

Messina²,

Mitchell³

et al. 2015

Orthopedics

View full text Add to dashboard Cite

show abstract

“…Apixaban is currently FDA-approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the prophylaxis of DVT, which may lead to PE, in patients who have undergone TKR or THR, for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. The predictable pharmacokinetics, limited medication interactions, lack of required laboratory monitoring, and potentially improved cost-effectiveness 48 render apixaban an attractive alternative to other anticoagulants such as warfarin. However, long-term safety data is not yet available, and RCT data is lacking in special populations.…”

Section: Discussionmentioning

confidence: 99%

Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review

Mandernach¹,

Beyth²,

Rajasekhar³

2015

TCRM

View full text Add to dashboard Cite

Venous thromboembolism (VTE) results in significant morbidity and mortality. The prevention and treatment of VTE is managed with anticoagulant therapy, historically parenteral anticoagulants such as unfractionated heparin, low molecular weight heparin, and fondaparinux, and oral vitamin K antagonists such as warfarin. In the last few years, several target-specific oral anticoagulants have been developed, including the direct thrombin inhibitor dabigatran and anti-Xa inhibitors rivaroxaban, apixaban, and edoxaban. The target-specific oral anticoagulants have proven to be noninferior to vitamin K antagonists and heparins in the prevention and treatment of VTE. This review will focus on the pharmacology, clinical trial data, and laboratory assessment of apixaban. Moreover, perioperative management, use in special populations, and management of bleeding complications in patients taking apixaban for the prevention and treatment of VTE will also be discussed.

show abstract

“…20 Por outro lado, Revankar et al, em uma avaliação econômica do uso de apixabana, mostrou que essa droga é uma opção benéfica para a prevenção de TVP pós-cirúrgico, em comparação com a enoxaparina. 21 A edoxabana é um inibidor direto oral do fator Xa. O estudo STAR E-3 comparou 30 mg de edoxabana uma vez ao dia, com início seis a 24 horas após a cirurgia, ou enoxaparina 20 mg, subcutâneo, duas vezes ao dia, começa 24 a 36 horas após a cirurgia por 11 a 14 dias depois de ATJ, em pacientes no Japão e Taiwan.…”

Section: Métodos Farmacológicosunclassified

Untitled

2019

Rev Bras Ortop

View full text Add to dashboard Cite

Introdução A artroplastia total de joelho (ATJ) é um procedimento cirúrgico seguro para alívio da dor e melhoria de limitações funcionais causadas pela artrose severa, nos casos em que o tratamento clínico não é mais efetivo. Entretanto, algumas complicações podem ocorrer. Uma complicação potencial é a trombose venosa profunda (TVP). Existem alguns fatores de risco para a ocorrência da TVP: idade acima de 60 anos, obesidade, uso de contraceptivos orais ou por adesivos, terapia de reposição hormonal, veias varicosas, doença inflamatória intestinal, histórico de TVP ou embolia pulmonar (EP), histórico familiar de trombose e tempo prolongado de garroteamento, se esse for usado na artroplastia. Song et al. fizeram um estudo observacional prospectivo com flebografia bilateral de membros inferiores em 109 pacientes, dentro de uma semana após a ATJ unilateral primária. Eles relataram que a incidência de TVP sintomática e TVP assintomática, após o procedimento cirúrgico, foi de 4,6 e 18,3%, respectivamente. 1 Basicamente, existem os métodos mecânicos e farmacológicos usados para prevenção de TVP. Métodos Mecânicos A mobilização precoce do paciente é a medida mais simples e barata para prevenir a formação de trombos. Existem outras Palavras-chave ► prótese total de joelho ► complicações ► trombose venosa ► prevenção Resumo Os autores descrevem uma atualização dos principais métodos de prevenção da trombose venosa profunda após artroplastia total do joelho, classificados em métodos mecânicos e farmacológicos. Reportam as principais drogas usadas, dosagem, riscos e benefícios comparativos.

show abstract

A Canadian Study of the Cost-Effectiveness of Apixaban Compared With Enoxaparin for Post-Surgical Venous Thromboembolism Prevention

Abstract: : This is the first economic evaluation of apixaban use for VTE thromboprophylaxis in the Canadian setting, and our study results show apixaban to be a cost-effective treatment alternative to preventive treatment with enoxaparin.

Cited by 22 publications

References 30 publications

Venous Thromboembolism Prophylaxis After Total Joint Arthroplasty

Venous Thromboembolism Prophylaxis After Total Joint Arthroplasty

Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review

Untitled

Contact Info

Product

Resources

About